Core Viewpoint - Inghams Group has denied media speculation regarding a potential sale of the company, asserting that it is not pursuing any discussions related to a sale [1][2]. Financial Performance - Inghams reported a net profit decline of 11.5% to A$89.3 million ($58.1 million) for the year ending June 28, with revenue decreasing by 3.4% to A$3.15 billion [3]. - EBITDA fell by 15% to A$392.2 million, while EBIT decreased by 6.2% to A$209.3 million, and earnings per share dropped by 11.5% to 24.2 cents [3]. Market Conditions - The company's results were impacted by a transition to a new supply contract with Woolworths, Australia's largest retailer, and challenging local market conditions, particularly in the final quarter [4]. - Core poultry volumes in Australia decreased by 2.5%, attributed to the Woolworths contract switch, while New Zealand saw a 5.3% increase in volumes [4][5]. Strategic Developments - The acquisition of Bostock Brothers in New Zealand contributed approximately 40 basis points to the group's growth, despite an overall decline in total group poultry volumes by 0.4% [5]. - Ongoing cost-of-living pressures affected the Quick Service Restaurant (QSR) segment, and bird flu incidents on non-Ingham farms led to reduced export volumes [6].

Core Insights - Traws Pharma announced positive topline results from studies on tivoxavir marboxil, showing its efficacy in treating H5N1 bird flu in ferrets, consistent with previous murine model results [1][2][3] - The company is conducting further studies in non-human primates, with data expected in Q1 2025, and plans to approach the FDA for accelerated approval under the "Animal Rule" [2][3] Company Overview - Traws Pharma is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for respiratory viral diseases, including bird flu and seasonal influenza [6] - The company is developing two drug candidates: tivoxavir marboxil for bird flu and seasonal influenza, and ratutrelvir for COVID-19 treatment [6] Product Details - Tivoxavir marboxil is designed to inhibit the influenza protein CAP-dependent endonuclease (CEN) and has shown potent in vitro activity against various influenza strains, including H5N1 [5] - The antiviral market for bird flu and seasonal influenza is estimated to represent a multi-billion dollar opportunity, driven by global health organizations and government tenders [5]